Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Biol Blood Marrow Transplant ; 13(3): 329-38, 2007 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-17317586

RESUMEN

In an attempt to abrogate the deleterious effects of graft-versus-host disease (GVHD), allogeneic transplantation for nonmalignant diseases was performed using high-dose CD34-cell infusion, partial T cell depletion, and no posttransplantation GVHD prophylaxis. Between 1998 and 2004, 16 patients with matched related donors were treated. Median age was 1.5 years (range, 5 months-18 years). The conditioning regimen consisted of busulphan 16 mg/kg, cyclophosphamide 200 mg/kg, antithymocyte globulin (ATG) 25 mg/kg, and fludarabine 200 mg/m(2). No GVHD prophylaxis was given. High doses of CD34 cells, positively selected by immunomagnetic beads, were infused at a median dose of 10.7 x 10(6) CD34/kg (range, 7.4-50 x 10(6)). A total of 1 x 10(5)/kg T cells were given. All patients engrafted, with no graft rejections. All were alive and well at a median of 37 months posttransplantation (range, 18-89 months). Only 1 patient developed chronic GVHD. No episodes of severe infection occurred during or after transplantation. Immunologic reconstitution with CD3/CD4 T cells > 200/microL was observed at a median of 117 days and that with naive T cells (CD4/CD45RA) at a median of 188 days posttransplantation. Our findings suggest that allogeneic transplantation from a matched family donor for nonmalignant disorders can be successfully performed using high doses of CD34 cells, moderate T cell depletion, and no posttransplantation immunosuppression.


Asunto(s)
Trasplante de Médula Ósea/métodos , Enfermedad Injerto contra Huésped/prevención & control , Depleción Linfocítica/métodos , Adolescente , Antígenos CD34 , Niño , Preescolar , Femenino , Supervivencia de Injerto , Humanos , Sistema Inmunológico/citología , Lactante , Masculino , Estudios Retrospectivos , Tasa de Supervivencia , Acondicionamiento Pretrasplante/métodos , Trasplante Homólogo , Resultado del Tratamiento
2.
J Infect Dis ; 189(11): 2023-6, 2004 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-15143469

RESUMEN

It is widely accepted that there is a causal association between Kaposi sarcoma-associated herpesvirus (KSHV) and Kaposi sarcoma (KS). However, the majority of individuals infected with KSHV never develop KS. Here, we present a unique familial case of classic KS, in which the disease occurs in 4 siblings who have no recognized underlying immunodeficiency. We examine risk factors that could play a role in this condition, including KSHV infection, KSHV DNA load, genetic variants of KSHV, infection with additional viruses, interleukin-6-promoter polymorphism, and HLA genotype. We hypothesize that a genetic susceptibility to KS, in combination with KSHV infection, may play an important role in the presented familial case.


Asunto(s)
Herpesvirus Humano 8 , Sarcoma de Kaposi/genética , Adulto , Anciano , Anciano de 80 o más Años , Anticuerpos Antivirales/sangre , ADN Viral/sangre , Femenino , Predisposición Genética a la Enfermedad , Antígenos de Histocompatibilidad Clase I/genética , Antígenos de Histocompatibilidad Clase I/inmunología , Antígenos de Histocompatibilidad Clase II/genética , Antígenos de Histocompatibilidad Clase II/inmunología , Humanos , Interleucina-6/genética , Interleucina-6/inmunología , Masculino , Persona de Mediana Edad , Linaje , Polimorfismo Genético/inmunología , Regiones Promotoras Genéticas/inmunología , Sarcoma de Kaposi/inmunología , Sarcoma de Kaposi/virología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA